Exec Chat: Steven Mickelsen Helps Acutus Translate Science Into Improved Outcomes
Executive Summary
Mickelsen, an electrophysiologist at the University of Iowa, recently joined the rapidly growing San Diego-area company as Chief Translational Science Officer and is helping to guide the company’s development of novel electrophysiology therapies to treat cardiac arrhythmias.
You may also be interested in...
Acutus Sells Left-Heart Access Business To Medtronic; Extends Its Cash Runway
The deal, potentially worth more than $85m, will allow Acutus to get more revenue from its core AcQMap electrophysiology mapping technology and invest in the development of its pulsed field ablation system.
Acutus Cuts Jobs To Reduce Cash Burn, Drive Adoption Of Cardiac Mapping System
The electrophysiology company announced it will reduce its workforce and take other cost-reduction measures to reduce its annual spending by $23m-$25m. Analysts suspect the company will need to raise more money from investors in 2022 or try to be acquired by a larger company.
Boston Scientific Shoots For Cardiac Ablation Leadership With $387M Farapulse Acquisition
Boston Scientific will exercise its option to buy the remaining 73% of Farapulse, the first company to market a pulsed field cardiac ablation system.